Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Rhea-AI Summary
Genelux (NASDAQ: GNLX) appointed Jason Litten, M.D. as Chief Medical Officer, effective January 2, 2026.
Dr. Litten will oversee clinical development and medical strategy as Genelux advances Olvi-Vec toward upcoming pivotal readouts in ovarian and lung cancer. He brings over 20 years of oncology development experience across biologics, small molecules, and cell therapies, with prior CMO roles at Chimeric Therapeutics and Artiva and senior positions at Juno, Clovis, and Amgen. In connection with his hire, Genelux granted an inducement stock option for 275,000 shares under the 2023 Inducement Plan, exercisable at the closing price on the grant date and vesting over four years (25% at one year, then monthly over 36 months).
Positive
- Appointed experienced oncology CMO with >20 years' development leadership
- Clinical leadership strengthened ahead of pivotal Olvi-Vec readouts
Negative
- Inducement option for 275,000 shares creates potential dilution risk
News Market Reaction – GNLX
On the day this news was published, GNLX gained 4.36%, reflecting a moderate positive market reaction. This price movement added approximately $7M to the company's valuation, bringing the market cap to $175M at that time.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.
“We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes,” said Thomas Zindrick, President, CEO, and Chairman of the Board. “He brings extensive experience in oncology drug development of innovative therapies, including a proven track record of leading complex programs from early development through late-stage trials. Jason’s insight and disciplined approach to clinical execution will support our momentum as we approach key readouts in ovarian and lung cancer and work to unlock the full clinical and commercial potential of Olvi-Vec as a best-in-class immunotherapy.”
Dr. Litten is a seasoned biopharmaceutical executive with over 20 years of experience spanning academia, large pharmaceutical organizations, and innovative biotechnology companies. He has led the design, execution, and interpretation of Phase 1-4 clinical trials in liquid and solid tumors, with expertise across biologics, small molecules, and cellular therapies.
Most recently, Dr. Litten served as Chief Medical Officer at Chimeric Therapeutics, Ltd., where he advanced first-in-human cell therapy programs in brain, gastrointestinal, and hematologic cancers. Prior to that, he was Chief Medical Officer at Artiva Biotherapeutics, Inc., where he built and led clinical development, operations, regulatory affairs, quality, and medical affairs functions. Earlier in his career, Dr. Litten held senior leadership roles at Optera Therapeutics Corp., Juno Therapeutics, Inc., Clovis Oncology, Inc., and Amgen Inc., contributing to global development strategies for novel oncology therapeutics.
Dr. Litten earned an M.D. from Emory University School of Medicine and a B.S. in Finance and Economics from Cornell University. He completed postdoctoral training in Pediatric Hematology & Oncology at the University of Texas Southwestern Medical Center at Dallas and is licensed as a physician and surgeon in California.
“I am honored to join Genelux at such a pivotal time,” said Dr. Litten. “Olvi-Vec represents a compelling therapeutic platform with potential across multiple tumor types, and I look forward to working with the team to execute our clinical strategy, prepare for future regulatory interactions, and ultimately bring new options to patients facing difficult-to-treat cancers.
In connection with his appointment, Dr. Litten was granted an inducement award of a stock option to purchase 275,000 shares of common stock under Genelux’s 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price per share equal to the closing price of Genelux’s common stock on The Nasdaq Capital Market on the date of grant. The inducement award will vest over four years, with
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan,” “look forward” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Dr. Litten’s expected contribution to Genelux, Olvi-Vec’s development plans and the realization of Olvi-Vec’s full potential. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Investor Contact
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
Media Contact
Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com
Source: Genelux Corporation
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4196792-0f6a-456e-b165-1a9302b7e413
FAQ
When did Genelux (GNLX) appoint Jason Litten as CMO?
What will Jason Litten oversee at Genelux (GNLX)?
What are the terms of Dr. Litten's inducement award at GNLX?
How does this hire affect Genelux's Olvi-Vec timeline?
Does Dr. Litten have prior CMO experience relevant to GNLX?
